Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant with AZD2014 or everolimus versus fulvestrant alone in ER-positive advanced breast cancer
2013-002403-34Phase 2Terminated
- Sponsor
- Queen Mary University of London
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Fulvestrant + AZD2014, Fulvestrant + everolimus and Fulvestrant alone (3 arms). Primary endpoint: Progression-free survival. Started Dec 2013; status: terminated.
02
Drugs
vistusertibeverolimusfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-002403-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002403-34.